Marker Therapeutics (NASDAQ:MRKR) Now Covered by LADENBURG THALM/SH SH

Equities researchers at LADENBURG THALM/SH SH began coverage on shares of Marker Therapeutics (NASDAQ:MRKR) in a research note issued on Tuesday, Benzinga reports. The brokerage set a “buy” rating and a $11.00 price target on the stock. LADENBURG THALM/SH SH’s price objective points to a potential upside of 157.01% from the company’s current price.

Marker Therapeutics Trading Up 4.1 %

Shares of MRKR traded up $0.17 during trading hours on Tuesday, hitting $4.28. The stock had a trading volume of 1,420 shares, compared to its average volume of 20,003. The company’s fifty day simple moving average is $4.28 and its 200 day simple moving average is $3.97. Marker Therapeutics has a 12-month low of $0.90 and a 12-month high of $9.68.

Institutional Investors Weigh In On Marker Therapeutics

A hedge fund recently raised its stake in Marker Therapeutics stock. International Assets Investment Management LLC lifted its holdings in shares of Marker Therapeutics, Inc. (NASDAQ:MRKR) by 1,000.0% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 11,000 shares of the company’s stock after acquiring an additional 10,000 shares during the quarter. International Assets Investment Management LLC owned 0.12% of Marker Therapeutics worth $60,000 as of its most recent filing with the SEC. Institutional investors and hedge funds own 22.39% of the company’s stock.

Marker Therapeutics Company Profile

Marker Therapeutics, Inc, a clinical-stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications in the United States. Its MultiTAA-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens and kill tumor cells.